Although, pCR rate is low in HR-positive breast cancer, patients with high grade/HER2-negative or luminal B tumors more frequently achieve pCR, which correlates with better survival and suggests the clinical value of differentiating luminal B from luminal A tumors before NAC [11, 12]. The gene discussed is ERBB2; the disease is breast cancer.